All News

Teresa Lovins, MD, highlights a study that showed a 14% increase in rates of safety planning within 2 weeks of a negative screening led to a 25% decrease in attempted suicides.

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

In a trial of over 112 000 US adults, researchers found that 14% started a GLP-1 receptor agonist after bariatric surgery.

The ACC provides evidence-based guidance on improving vaccine uptake in vulnerable patients, addressing vaccine hesitancy, and improving overall vaccine access.

ESC 2025: The first global investigation of evidence for the potential positive connection is encouraging, but more research is needed to understand causality.

Your daily dose of the clinical news you may have missed.

Infectious disease and family medicine experts share guidance on vaccine policy changes, patient communication, and boosting vaccine confidence.

Teresa Lovins, MD, sees at least 1 or 2 patients a week who have suicidal ideation. Too many of them are at risk for an attempt within a month of those visits.

MRGPRX2 antagonism is the only known mechanism of action designed to modulate mast cells and sensory neurons, both key drivers of lesions and itch in AD.

A survey by The Physicians Foundation found most US clinicians feel that faulty medical information has increased in the last 5 years and half say it has increased significantly.

Your daily dose of the clinical news you may have missed.

Discover the latest advancements in atopic dermatitis treatment, including new topical agents and biologics, enhancing care for patients with moderate to severe conditions.

Mental health issues affect half the population at some point during a lifetime. Teresa Lovins, MD, says FPs are often the first to learn that "something is going on."

The FDA removed the prior requirement for a person who is already diagnosed with a cardiovascular disease.

One-Day TMS condenses transcranial magnetic stimulation therapy treatment from a daily month-long process to 1 day, with rapid and durable results, NeuroStim says.

Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.

People with obesity may shun basic primary care for fear of shaming, lectures, inhospitable equipment, and simple lack of respect from clinicians, authors found.

Your daily dose of the clinical news you may have missed.